Barrett-Connor E
Women Health. 1986 Fall-Winter;11(3-4):179-95. doi: 10.1300/j013v11n03_13.
The female hormone estrogen is widely prescribed to postmenopausal women. Its major documented benefit is prevention of bone mineral loss, which is a major risk factor for fracture in the elderly. Its clearly documented risk is promotion of cancer of the endometrium. There is a growing body of data that suggests that postmenopausal estrogen therapy reduces the risk of cardiovascular disease. This benefit, if real, may be lost when a cyclic progestin is added to reduce the risk of cancer. Further studies are needed to provide a firmer basis for balancing these risks and benefits.
女性激素雌激素被广泛开给绝经后女性。其主要有记录的益处是预防骨矿物质流失，而骨矿物质流失是老年人骨折的主要风险因素。其明确有记录的风险是促进子宫内膜癌。越来越多的数据表明绝经后雌激素疗法可降低心血管疾病风险。如果这一益处属实，那么在添加周期性孕激素以降低癌症风险时可能会丧失。需要进一步研究以提供更坚实的基础来权衡这些风险和益处。
